Tacrine was the first drug to display beneficial effects on cognitive impairment of Alzheimer
Disease (AD) patients. Unfortunately, many treated patients displayed related hepatotoxicity …

Tacrine was the first drug approved for the treatment of Alzheimer's disease (AD) in 1993,
which was withdrawn in 2013 due to its hepatotoxicity. However, new, non-hepatotoxic …

Herein we have reviewed our recent developments for the identification of new tacrine
analogues for Alzheimer's disease (AD) therapy. Tacrine, the first cholinesterase inhibitor …

Tacrine was the first drug approved by FDA (US) for the treatment of Alzheimer's disease
suffering patients. Nowadays, this agent has been withdrawn from the clinics due to …

Notwithstanding the clinical use of tacrine was hampered by severe hepatotoxicity, tacrine
still remains a reference scaffold in the search for new efficient drugs for Alzheimer's disease …

To date, the pharmacotherapy of Alzheimer's disease (AD) has relied on
acetylcholinesterase (AChE) inhibitors (AChEIs) and, more recently, an N-methyl-D …

Our endeavors in the design, synthesis, and biological assessment of five-membered-ring-
fused tacrines as potential therapeutic agents for Alzheimer's disease are summarized …

Alzheimer's disease (AD) is a neurodegenerative disorder, which is complex and
progressive; it has not only threatened the health of elderly people, but also burdened the …

Background: The design of multifunctional agents represents one of the most active
research field in medicinal chemistry. In particular, tacrine, a well known …

Tacrine is a potent inhibitor of cholinesterases (acetylcholinesterase and
butyrylcholinesterase) that shows limiting clinical application by liver toxicity. In spite of this …